Navigation Links
ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments
Date:10/25/2008

st humanized interleukin-6 (IL-6) receptor-inhibiting monoclonal antibody studied for the treatment of RA. Studies demonstrate that reducing the activity of IL-6, one of several key cytokines involved in the inflammatory process, relieves both inflammation of the joints and certain systemic effects of RA. The extensive clinical development program conducted by Roche includes five Phase III clinical studies and has enrolled more than 4,000 patients in 41 countries, including the United States. Four Phase III studies are completed and have reported meeting their primary endpoints. A fifth Phase III study, the LITHE trial evaluating ACTEMRA in RA is an ongoing two-year study, which is expected to report complete data evaluating the effects of ACTEMRA on the inhibition of structural joint damage in 2009. ACTEMRA is currently under review in the United States and Europe.

ACTEMRA is part of a co-development agreement between Roche and Chugai Pharmaceutical Co. In June 2005, ACTEMRA was launched by Chugai in Japan as a therapy for Castleman's disease; in April 2008, additional indications for rheumatoid arthritis, juvenile idiopathic arthritis and systemic-onset juvenile idiopathic arthritis were also approved in Japan.

The serious adverse reactions reported in ACTEMRA clinical studies include serious infections, gastrointestinal perforations and hypersensitivity reactions including anaphylaxis. The most common adverse reactions reported in clinical studies were upper respiratory tract infection, nasopharyngitis, headache, hypertension and increased ALT. Increases in liver enzymes (ALT and AST) were seen in patients; these increases were generally mild and reversible, with no evidence of hepatic injuries. Laboratory changes, including increases in lipids (total cholesterol, LDL, HDL, triglycerides) and decreases in neutrophils and platelets, were seen in patients without association with clinical outcomes. Treatments that suppress the immune system, such as A
'/>"/>

SOURCE Hoffmann-La Roche Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies
2. New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients
3. International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet
4. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
5. Two Pivotal Phase III Studies for Roches ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms
6. Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD
7. Successful Results for Mymetics Corporations Mucosal HIV/AIDS Vaccine Viral Challenge Significantly Exceeds Expectations
8. Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel
9. Hibernation-On-Demand Drug Hydrogen Sulfide Significantly Improves Survival After Extreme Blood Loss
10. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
11. New Study: Pine Bark Significantly Reduces Menstrual Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... FRANCISCO, July 31, 2014 Nektar Therapeutics (Nasdaq: ... second quarter ended June 30, 2014. Cash ... $301.4 million as compared to $309.1 million at March 31, ... for Nektar as we look forward to significant milestones for ... Robin, President and Chief Executive Officer of Nektar. "The first ...
(Date:7/31/2014)... 2014  UBM Medica US announces that ... oncologists, presents exclusive slide shows dealing with communication in ... cancer care. Cancer Network, the ... news, blogs, and podcasts about the latest clinical findings. ... , End-of-life care is challenging for even ...
(Date:7/31/2014)... , July 31, 2014  Decision Resources Group ... market intelligence product Marketrack to now include ChinaTrack; the ... device landscape in an interactive dashboard providing detailed brand-level ... volumes at a hospital level. Other key ... Updated data feed: In addition to end-user surveys of ...
Breaking Medicine Technology:Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 2Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 3Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 4Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 5Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 6Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 7Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 8Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 9Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 10Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 11Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 12Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 13Nektar Therapeutics Reports Financial Results for the Second Quarter of 2014 14Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 2Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 3Decision Resources Group Announces First Medical Device Account Targeting Tool in China 2
... Calif. and DUBAI, United Arab Emirates, Feb. 10, 2011 ... Masimo (Nasdaq: ... Hospital to Masimo rainbow® SET Pulse CO-Oximetry™ technology for ... Hospital the first hospital in the UAE to feature ...
... Some drug manufacturers are aggressively pushing legislative proposals ... would undermine electronic prescribing,s (e-prescribing) proven safety and ... said today. "This campaign undermines ... reducing prescription drug costs. Doctors should be able ...
Cached Medicine Technology:Mafraq Hospital Becomes First in United Arab Emirates to Deploy Masimo rainbow SET Pulse CO-Oximetry for State-of-the-Art Noninvasive Patient Monitoring 2Mafraq Hospital Becomes First in United Arab Emirates to Deploy Masimo rainbow SET Pulse CO-Oximetry for State-of-the-Art Noninvasive Patient Monitoring 3Mafraq Hospital Becomes First in United Arab Emirates to Deploy Masimo rainbow SET Pulse CO-Oximetry for State-of-the-Art Noninvasive Patient Monitoring 4Mafraq Hospital Becomes First in United Arab Emirates to Deploy Masimo rainbow SET Pulse CO-Oximetry for State-of-the-Art Noninvasive Patient Monitoring 5Mafraq Hospital Becomes First in United Arab Emirates to Deploy Masimo rainbow SET Pulse CO-Oximetry for State-of-the-Art Noninvasive Patient Monitoring 6Mafraq Hospital Becomes First in United Arab Emirates to Deploy Masimo rainbow SET Pulse CO-Oximetry for State-of-the-Art Noninvasive Patient Monitoring 7PCMA: Some Drugmakers Lobbying to Limit E-Prescribing of Generics, Drug Safety Checks 2
(Date:7/31/2014)... Joseph M. Lee, M.D., M.S., R.P.V.I, ... a leading provider of quality cardiovascular and internal medicine ... Dr. Lee is a board certified cardiologist with a ... addition to his position at CDHV, Dr. Lee is ... Columbia University Medical Center. Dr. Lee is board certified ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Women in ... take charge of their financial future. The Independent ... has opened registration for 6 upcoming Los Angeles area ... for women, and with input from Kim Kiyosaki, a ... It’s Rising Time) who is passionate about women’s financial ...
(Date:7/31/2014)... steadily in the U.S in recent years. According to ... number of individuals reporting past year heroin use almost ... suggests the increase may be linked to prescription opioid ... use to heroin use, with POs providing the entryway ... This drug-use trajectory appears to have become increasingly common ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Clifton Dental ... the application of topical fluoride treatments to their adult ... and help with tooth sensitivity in patients that exhibit ... an infection that is commonly known as “tooth decay” ... tissues of the teeth. , Fluoride therapy ...
(Date:7/31/2014)... Reinberg HealthDay Reporter THURSDAY, ... rather than war experiences, are a source of drinking problems ... study suggests. Setbacks such as job loss, divorce and ... make as many as 13 percent of vets turn to ... has an important effect on mental health in the short ...
Breaking Medicine News(10 mins):Health News:ColumbiaDoctors of the Hudson Valley Welcomes Joseph M. Lee, M.D., M.S., R.P.V.I. 2Health News:ColumbiaDoctors of the Hudson Valley Welcomes Joseph M. Lee, M.D., M.S., R.P.V.I. 3Health News:The Independent Woman to Offer Financial Workshops in the Los Angeles Area - Developed by Women for Women 2Health News:NYU CDUHR researchers look at prescription opioid abuse among young adults in NYC 2Health News:NYU CDUHR researchers look at prescription opioid abuse among young adults in NYC 3Health News:NJ Top Dentists Approved, Clifton Dental Associates Now Actively Recommending the Application of Topical Fluoride Treatments to Adults 2Health News:Civilian Life, Not Combat, May Drive Many Veterans to Drink 2Health News:Civilian Life, Not Combat, May Drive Many Veterans to Drink 3
... Americans with muscular dystrophy die 10 to 12 years younger ... Sept. 14 issue of Neurology , the medical journal ... gap, which was calculated on the basis of 20 years ... annals of research into racial disparities in health care, say ...
... Colorado at Boulder study sheds light on the brain mechanisms ... helpful in improving treatments for the millions of people who ... study, CU-Boulder psychology Professor Yuko Munakata and her research colleagues ... nerve cell suppresses activity in another, is a critical aspect ...
... National Hispanic Science Network on Drug Abuse awarded the ... Investigator to Alice Cepeda, sociology professor and associate director ... Graduate College of Social Work, University of Houston. ... annual conference in New Orleans. , The National ...
... By Jenifer Goodwin HealthDay Reporter , MONDAY, ... levels of thimerosal, a mercury-laden preservative that used to be ... autism than infants exposed to only a little thimerosal, new ... who worry that vaccination raises their children,s risk for autism, ...
... 13 (HealthDay News) -- Women can be vulnerable to ... part of a condition called preeclampsia. And now ... which women are most prone to preeclampsia in late ... relies on so-called "metabolic profiling" to track telltale metabolites ...
... mental aging reveals a good news-bad news situation. The bad ... to varying degrees. The good news is the drops are ... study published by the American Psychological Association. "There ... called crystallized intelligence decline at older ages," said study author ...
Cached Medicine News:Health News:Blacks with muscular dystrophy die 10-12 years younger than whites: New study 2Health News:CU-Boulder study sheds light on how our brains get tripped up when we're anxious 2Health News:CU-Boulder study sheds light on how our brains get tripped up when we're anxious 3Health News:University of Houston researcher receives National Award of Excellence in Research 2Health News:More Evidence That Vaccines Don't Cause Autism 2Health News:More Evidence That Vaccines Don't Cause Autism 3Health News:Test Might Spot Women at High Risk for Pregnancy Complication 2Health News:Test Might Spot Women at High Risk for Pregnancy Complication 3Health News:New study reconciles conflicting data on mental aging 2Health News:New study reconciles conflicting data on mental aging 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: